Kindstar Globalgene Technology, Inc. (HKEx: 09960) disclosed that it repurchased 10,500 ordinary shares on 22 June 2026 via on-market transactions, paying between HK$0.96 and HK$0.98 per share. The volume-weighted average price was HK$0.9719, bringing total consideration to approximately HK$0.01 million.

Following the repurchase, the company’s issued share capital (excluding treasury shares) declined by 0.00102% to 1.03 billion shares, down from 1.03 billion shares previously. Treasury shares rose to 7.27 million, keeping the overall share count unchanged at 1.04 billion.

The buyback was executed under the general mandate approved on 05 June 2026, which authorises the company to repurchase up to 103.43 million shares. To date, Kindstar Globalgene has acquired 210,000 shares under this mandate, representing 0.0203% of the issued shares outstanding on the mandate date.

In accordance with Hong Kong Stock Exchange regulations, the company is subject to a moratorium on new share issues or sales of treasury shares until 22 July 2026.